跳至主要内容
临床试验/KCT0000388
KCT0000388已完成未知

Evaluation of efficacy and safety after treatment of twice daily NovoMix30 in patients with type 2 diabetes A multi-centre, open-labelled, single-arm tria (Phase 4)

Inje University Sanggye Paik Hospital0 个研究点目标入组 60 人开始时间: 待定最近更新:
适应症

试验速览

阶段
未知
状态
已完成
入组人数
60

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional Study

入排标准

年龄范围
18(Year) 至 o Limit(—)
性别
All

入选标准

  • Type 2 diabetes according to WHO classification.
  • 1) Treated with OAD(s) for at three months.
  • 2) Age = 18 years.
  • 3) Body mass index (BMI) = 25.0 kg/m2.
  • 4) Glycosylated hemoglobin (HbA1c) = 7.5 % and = 10.0 % (both inclusive)

排除标准

  • The patients who have history of drug or alcohol abuse, were treated with any other drug known to affect blood glucose (i.e., MAO-inhibitors, beta-adrenergic agents, anabolic steroids, and systemic glucocorticoids), have impaired renal function with serum creatinine = 1.7 mg/dL, have cardiac disease defined as: decompensated heart failure (NYHA classification III and IV), unstable angina pectoris, myocardial infarction within the last 12 months, or severe uncontrolled hypertension (systolic blood pressure when seated > 180 mmHg and/or diastolic blood pressure > 110 mmHg), or have proliferative retinopathy and/or advanced neuropathy as judged by the investigator. Pregnant or breast-feeding, or have the intention to become pregnant.

研究者

相似试验

Evaluation of efficacy and safety after treatment of... | 临床试验